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Abstract
Abnormal excitatory glutamate neurotransmission and plasticity have been implicated in schizophrenia and affective
disorders. Gria12/2 mice lacking GluA1 subunit (encoded by Gria1 gene) of AMPA-type glutamate receptor show robust
novelty-induced hyperactivity, social deficits and heightened approach features, suggesting that they could be used to test
for anti-manic activity of drugs. Here, we tested the efficacy of chronic treatment with established anti-manic drugs on
behavioural properties of the Gria12/2 mice. The mice received standard mood stabilizers (lithium and valproate) and
novel ones (topiramate and lamotrigine, used more as anticonvulsants) as supplements in rodent chow for at least 4 weeks.
All drugs attenuated novelty-induced locomotor hyperactivity of the Gria12/2 mice, especially by promoting the
habituation, while none of them attenuated 2-mg/kg amphetamine-induced hyperactivity as compared to control diet.
Treatment with lithium and valproate reversed the elevated exploratory activity of Gria12/2mice. Valproate treatment also
reduced struggling behaviour in tail suspension test and restored reciprocally-initiated social contacts of Gria12/2 mice to
the level shown by the wild-type Gria1+/+ mice. Gria12/2 mice consumed slightly more sucrose during intermittent
sucrose exposure than the wild-types, but ran similar distances on running wheels. These behaviours were not consistently
affected by lithium and valproate in the Gria12/2 mice. The efficacy of various anti-manic drug treatments on novelty-
induced hyperactivity suggests that the Gria12/2 mouse line can be utilized in screening for new therapeutics.
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Introduction
Abnormal major excitatory neurotransmission and neuroplas-
ticity, driven by glutamatergic neurotransmitter system, have been
implicated in schizophrenia and mood and anxiety disorders [1,2].
Psychotic, cognitive and emotional disturbances are linked to
hyperactive glutamatergic neurotransmission in the brain [3].
These disturbances can be reproduced in animals and human
subjects by blockade of N-methyl-D-aspartate (NMDA) receptors,
with a mechanism thought to involve enhanced non–NMDA
receptor-mediated glutamate transmission [4,5] and to be
attenuated by agents inhibiting presynaptic glutamate release
[6,7]. Hyperglutamatergic state in the frontal cortical areas [8] and
upregulated markers of excitotoxicity and neuroinflammation in
the post-mortem frontal cortex [9] have been also observed in
bipolar patients. Several susceptibility genes encoding for gluta-
mate receptor subunits, including the Gria1 gene encoding for
GluA1 subunit of AMPA-type glutamate receptor (previously
named GLUA1, GluR1, GluRA, GluR-A [10]), have been
identified for bipolar disease [11,12]. Most of them are overlap-
ping with schizophrenia [13,14], as these two illnesses share many
behavioural characteristics.
An interesting finding has been the decreased GluA1 subunit
expression in the post-mortem hippocampus, thalamus and frontal
cortex of schizophrenic patients [15–19] and in the striatum of
bipolar patients [20]. Mice lacking the GluA1 subunit [21] have
been suggested to mimic some features of schizoaffective disorder
and schizophrenia [22,23]. These animals are abnormally active in
the open field [21,22,24–26], but have a similar locomotor profile
as wild-type animals in familiar home-cage environment [24].
Exaggerated exploration response provoked by a new object in the
cage further point to abnormal reactivity to novel situations,
although the Gria12/2 animals are known to habituate and
recognize a familiar object [25]. Furthermore, abnormalities in
working memory [21,27,28] and increased impulsive behaviour
have been observed in the Gria12/2 mice [23]. These mice also
exhibit a deficiency in pre-pulse inhibition and aberrant social
interaction [25,29], which resemble characteristic features seen in
schizophrenic patients.
Here, we have focused on pharmacological features of the
Gria12/2 mouse line, relevant for some positive symptoms of
schizophrenia and/or mania, using a battery of behavioural tests
to assess the predictive validity of the mouse model.
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Materials and Methods
Ethics
All animal testing procedures were approved by the State
Provincial Government of Southern Finland (ESAVI-0010026/
041003/2010). All efforts were made to minimize the number and
suffering of animals.
Animals
Gria12/2 mice and their Gria1+/+ wild-type (WT) controls
were from heterozygous breeding, generated previously by
inactivation of the Gria1 gene [21] and genotyped as reported
elsewhere [26]. The Gria12/2 mouse line is available at the
Jackson Laboratory (B6N.129-Gria1tm2Rsp/J, stock number:
019012). During experiments, mice were individually-housed or
grouped-housed in same-sex cages under standard laboratory
conditions (12-h light-dark cycle; lights on at 6:00 A.M.; temper-
ature 20–23uC; relative humidity 50–60%; aspen chip beddings).
Drugs
The powdered laboratory chow (R36, Lantma¨nnen Lantbruk,
Stockholm, Sweden and RM1 (E) SQC FG, 811004, Special Diet
Services, Essex, UK) was available ad libitum and it was mixed
homogenously with drugs as follows: lithium carbonate (Sigma-
Aldrich Corp St. Louis, MO USA) was added 1.2 g/kg chow for
the first week and 2.4 g/kg until the end of treatment; sodium
valproate (Deprakine, Sanofi Aventis Oy) 10 g/kg for the total
treatment time; topiramate (Topiramat Ratiopharm) 27 mg/kg
for the total treatment time; lamotrigine (Lamotrigin Ratiopharm)
75 mg/kg for the total treatment time. Doses aimed at human
therapeutic levels and were based on the literature [30,31] or pilot
studies. Lithium and valproate group had free access to additional
saline bottles to prevent possible ion imbalances during chronic
treatments [32]. Control chow was made in the same way but
without drugs. Animals were observed daily for any significant
body weight changes or toxicity signs during the treatments.
Drug Concentrations
Lithium and lamotrigine concentrations were analysed in
hospital laboratories from blood samples of mice taken after the
test of locomotor activity in novel environment. Trunk blood was
collected by decapitation and serum separated by centrifugation.
Concentration of lithium was determined by a colorimetric
method [33] in NordLab Oulu (Oulu, Finland) and that of
lamotrigine by a liquid chromatography after solid-phase extrac-
tion [34] in Rinnekoti-Foundation Laboratory (Espoo, Finland).
Experimental Design
Animals received drug treatments in their diet for 28 days,
followed by behavioural testing while they still continued on the
diets. Experimental design is presented in Fig. 1. We used test
batteries to measure sets of specific behavioural features. The test
order as well as a recovery break between the tests was designed to
minimize the effect of previous test on subsequent ones. The first
battery consisted of elevated-plus maze, forced swimming and
locomotor activity tests in this order for two cohorts. In the second
test battery, the animals were tested for sucrose preference using
the two-bottle choice test to evaluate hedonistic behaviour towards
sucrose, followed by open field test combined with new object
installation, tail-suspension test, social interaction test and
locomotor activity test after acute psychostimulant injection as
the last test (the drug treatments lasted up to 2 months).
Locomotor activity test was performed in several independent
cohorts of WT and Gria12/2 mice and at the end of the first test
battery and the results were pooled. All tests were performed
between 08:00 and 14:00 h. In order to study sucrose drinking and
wheel running, mice were separated to individual cages when the
treatments began (4 weeks before the beginning of test) to
minimize the effect of acute social isolation on hedonistic behavior
[35] and this housing was kept throughout this battery of tests. The
nesting material was provided in cages [36,37]. Between the tests,
the animals were handled at least two times weekly for body
weight measurement or for changing to clean cages. Also, for
certain time period the environment was enriched with running
wheels to assess hedonistic behavior.
Locomotor activity (LA) in a novel environment was observed in
plastic cages (40630620 cm) as described in detail [24]. Animals
were habituated to the experimental room at least for 1 h before
the test. Horizontal movements of eight to ten mice, placed in
visually isolated cages in a sound-attenuated room at light intensity
of 175 lx, were simultaneously recorded for 2 h using EthoVision
Color-Pro 3.0 video tracking software (EthoVision System, Noldus
Information Technology, Wageningen, Netherlands). All treat-
ment groups are listed in Table 1.
Elevated plus maze (EPM) test was used to assess mouse anxiety
[38]. The maze was made of grey plastic, elevated 50 cm from the
floor level. It consisted of a central platform (565 cm), two open
arms (5640 cm with a 0.2 cm edge) and two enclosed arms
(5640620 cm). The mice were placed individually on the central
platform facing the open arm and allowed free exploration of the
maze for 5 min. Central square was defined until 2 cm out of the
central platform, allowing detection of the centre of animal.
Movements were recorded and analysed automatically with the
EthoVision software.
Forced swimming test (FST) and tail suspension test (TST) were
done to assess animal’s coping with despair-like condition [39].
FST [24,40,41] was conducted so that each mouse was placed for
6 min individually in transparent cylindrical beakers (height
25 cm, diameter 15 cm) containing 3 l of water (23uC). In TST
[24,42], the mice were tape-attached individually by their tails on
elevated metal bar for 6 min. Behavior of each mouse was video-
recorded and analysed later by data acquisition program
Ethograph (Ethograph software 2.06, RITEC, St. Petersburg,
Russia) for the last 4 min of the tests. Behavioural analysis was
focused on the mouse immobility which was indicated when the
animal floated passively, making only small movements with the
hind paws and/or tail to prevent sinking in the water during FST
or when no struggling signs were obvious during TST.
Figure 1. Experimental schedule for different cohorts of mice.
LA, locomotor activity test; EPM, elevated plus maze test; FST, forced
swimming test; SD, sucrose drinking; RW, running wheel access; OF,
open field test; TST, tail suspension test; SI, social interaction test;
AMPH, D-amphetamine-induced LA test.
doi:10.1371/journal.pone.0100188.g001
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Sucrose preference alone (SD) or in combination with running
wheel (RW) was performed to assess hedonic propensity of the
mice [43]. Voluntary sucrose drinking [8% weight/volume (w/v)]
was evaluated using short-term intermittent protocol [44,45]: on
alternate days the mice obtained access to choose between water
and sucrose. The alternation of sucrose-free and sucrose days (S1,
S2 and S3) was repeated 3 times, and thereafter the alternation
was repeated 3 times (S4, S5 and S6) with running wheels (RW;
ENV-044 model; Med Associates, Inc., St. Albans, Vermont,
USA). The position of water and sucrose bottle was switched
pseudo-randomly to prevent the development of place preference
towards the sides. Fluid intake and body weights were monitored
daily. Sucrose solution intake (in ml) was calculated by dividing
loss of sucrose bottle weight with 1.08 [weight in grams of 1 ml of
8% (w/v) sucrose solution]. Sucrose preference (%) was calculated
as a percentage of sucrose intake out of the total fluid intake
(sucrose plus water).
Open field (OF) test combined with new object exploration was
performed to evaluate anxiety and mouse explorative activity [46].
The animals were placed individually on the centre of empty cage
(33655619 cm) divided into fifteen squares (11611 cm) initially
for 3 min. Testing was performed at the light intensity of 175 lx.
Then, a round, textured object (diameter = 4 cm) with three 1-cm
holes was placed on the centre for the next 3 min [41]. Mouse
behaviour was video-recorded and analysed later by Ethograph for
the last 3 min of the test. Arena of the OF was divided into
peripheral and central zones in the video tracking software
(EthoVision), which was used to track the mouse automatically for
the whole 6 min duration of the test. Object-related behaviours
(sniffing, manipulation and nose-pokes of the object) were counted
as total object interactions. Other behaviours including the
rearing, locomotion and individual behaviours (any other behavior
which does not include locomotion) were divided to central and
peripheral behaviours according to the virtual zones of the OF.
Social interaction (SI) was evaluated for 10 min on a new
territory among animals receiving the same treatment [41]. Two
or three animals were simultaneously introduced to a novel cage
with fresh bedding. The behaviour of animals was video-recorded.
Behavior of every mouse in the temporarily-formed group was
analysed by the Ethograph software for (1) individual behavior
without contacts with other members, such as locomotor activity,
(2) reciprocal (simultaneously-initiated) contacts, and (3) passive
contacts initiated by other group members. All observed contacts
were non-aggressive, although aggressive behaviour was expected.
Response to psychostimulants was tested 30 min after a single
i.p injection of 2 mg/kg amphetamine diluted in saline (D-
amphetamine sulphate, Dexedrine, GlaxoSmithKline, Brentford,
UK) in a volume of 10 ml/kg. Mouse locomotion was monitored
for 1 h in a novel arena by using the EthoVision system and
software.
Statistics
Statistics were carried out using PASW Statistic 18 software
(SPSS Inc., Chicago, IL, USA). Multivariate ANOVA (two-way)
followed by a Bonferroni (p,0.05) post hoc test was used to
analyse the data obtained from EPM, FST, TST, new object
exploration and social activity tests. For the repeated measure-
ments such as locomotor activity and sucrose consumption,
analysis for repeated measurements followed by a Bonferroni post
hoc test (p,0.05) was applied. Kaplan-Meier survival analysis with
a Mantel-Cox non-parametric test (p,0.05) was used to analyse
the latencies to immobility, to the contact with the new object and
to the social contact. Spearman’s correlation coefficient was used
to test correlation between sucrose drinking and activity on
Table 1. Characteristics of the treatment groups and drug concentrations.
Treatment Gender
Genotype (number
of animals)
Age
(weeks)
Initial body
weight (g)
Final body
weight (g)
Drug concentration
in blood
Control Male WT (16) 29.463.1 31.660.9 33.960.9*** /
Gria12/2 (10) 30.162.2 29.160.9 31.660.9*** /
Female WT (11) 15.760.7 20.260.2 22.060.2*** /
Gria12/2 (10) 22.364.0 21.161.0 23.760.9*** /
Lithium Male WT (8) 21.061.8 29.660.6 29.760.5 0.760.1
Gria12/2 (7) 20.662.4 28.060.9 28.260.6 0.860.1
Female WT (13) 23.762.3 22.560.6 23.460.7 0.760.1
Gria12/2 (12) 23.262.0 23.961.0 24.060.7 0.960.1
Valproate Male WT (13) 14.760.3 24.760.6 25.760.4 /
Gria12/2 (10) 25.765.6 24.961.4 26.761.0 /
Female WT (4) 14.661.3 17.861.5 21.161.0 /
Gria12/2 (4) 17.362.8 18.561.1 20.160.7 /
Topiramate Male WT (8) 16.760.7 28.061.0 30.161.2*** /
Gria12/2 (8) 21.462.8 27.660.7 29.060.7** /
Female WT (9) 17.960.7 22.460.8 23.960.7** /
Gria12/2 (10) 16.461.0 20.260.6 21.960.8** /
Lamotrigine Female WT (8) 33.467.4 23.461.0 23.160.7 3.660.4#
Gria12/2 (9) 33.864.1 25.161.0 24.360.7 5.060.4
Treatment groups, ages at the time of locomotor activity tests in novel cages, and body weights at the beginning and end of treatments are showed. Drug
concentrations were analysed from serum samples collected after the locomotor activity tests and presented in mM (lithium) or mM (lamotrigine). Data are means 6
SEM. *p,0.05, **p,0.01, ***p,0.001 compared to body weight at the beginning of treatments (paired t-test), #p,0.05 for the genotype difference (unpaired t-test).
doi:10.1371/journal.pone.0100188.t001
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running wheels. Two-tailed t-test was used to compare differences
in results for body weights (paired), drug concentrations (unpaired)
and LA (unpaired) obtained in different cohorts. All behavioural
elements or group of the elements obtained by the Ethograph
software were statistically analysed in four measurements: total
duration (sum of the duration of the element during the test),
medial duration (ratio of the element duration to its total
frequency), total frequency, and relative frequency (ratio of the
element frequency to the sum of all frequencies of the observed
elements).
Results
Chronic Treatment with Mood Stabilizers Lithium and
Valproate and Effects on Hyperactivity of Gria12/2 Mice
As locomotor activity tests were performed in several cohorts
with different experimental schedules (as an independent test and
at the end of the first battery, Fig. 1), we analysed statistically
whether the previous tests affected the later ones, by using t-tests
within each 6 experimental groups. No difference was observed in
the total 2-h locomotor activity within the control-treated Gria12/
2 mice (t18 = 0.02, p.0.05) between the separate test [571645 m
(10), mean 6 SEM, (n)] and the last test of the first battery
[572642 m (10)], nor within the corresponding groups of control-
treated WT mice [t25 = 0.25, p.0.05, 308625 m (12) and
300622 m (15)]. Nor were there any differences in LA between
independently performed and after EPM and FST performed tests
within the lithium-treated Gria12/2 mice [t17 = 1.47, p.0.05,
417651 m (7) and 509638 m (12)], lithium-treated WT mice
[t19 = 0.47, p.0.05, 281623 m (8) and 302631 m (13)], valpro-
ate-treated Gria12/2 mice [t12 = 1.17, p.0.05, 426624 m (7)
and 375636 m (7)] nor valproate-treated WT mice [t15 = 0.33, p.
0.05, 240618 m (7) and 229625 m (10)]. We conclude that
previous testing experience did not influence the novelty-induced
LA.
In the first 60-min of LA test, there was a significant genotype6
treatment6gender interaction (F2,106 = 3.20, p,0.05) after three-
way ANOVA. Bonferroni post-hoc comparisons showed that
female and male Gria12/2 mice travelled longer distances than
WT mice, in all treatment groups (p,0.05). There were no
significant gender differences in LA scores within Gria12/2 mice
on control-, lithium- or valproate-diets (p.0.05), nor within the
WT mice on these diets (p.0.05). Both lithium (p,0.05) and
valproate (p,0.05) treatments were efficient in reducing locomotor
hyperactivity of female Gria12/2 mice compared to control
treatment. The drugs did not affect LA of WT mice in comparison
to control diet. Valproate-treated Gria12/2 (p= 0.075) and WT
(p= 0.064) male mice tended to show reduced LA compared to
respective control-treated mice. Thus, only a slight difference in
response of female and male Gria12/2 mice to the lithium
treatment appeared during the first 60-min of the test. Statistical
analysis showed that gender did not interact with other factors in
the second 60-min of exposure to novel cages, when the effect of
the drugs on the locomotor activity was predominant (Fig. 2).
Because of that, we analyzed below pooled female and male data
also for the first 60-min of the test using two-way ANOVA and
these results are presented on Fig. 2C.
Locomotor activity of Gria12/2 mice during the first 60-min
exposures to novel environment after the chronic drug treatments
was markedly increased as compared to that of WT mice
(F1,112 = 101.17, p,0.001) (Fig. 2A–C). Only valproate-treated
Gria12/2 had reduced LA as compared to control Gria12/2
mice (F2,112 = 10.18, p,0.001). The LA of the Gria12/2 mice
continued to be higher than that of WT mice till the end of the 2-h
monitoring period, but cumulative LA during the last 60 min
showed that both lithium and valproate were efficient in reducing
LA in Gria12/2 mice (F2,112 = 4.82, p,0.05 for genotype 6
treatment interaction), but not in WT animals (Fig. 2D). Thus,
chronic treatments led to increased habituation of the Gria12/2
mice. Indeed, the effects were observed only after 15 min by
valproate and after 40 min by lithium (Fig. 2B), and the reductions
were more pronounced for 60–120 min than 0–60 min periods
(Fig. 2C and D). The differences between treatments were
indistinguishable after 70 min (Fig. 2B).
Effects on Elevated Plus-maze Test and Open Field
Exploration
Gria12/2 mice visited the centre of the elevated plus-maze
more frequently than the WT mice (F1,54 = 5.86, p,0.01) and
spent less time in the closed arms (F1,54 = 16.10, p,0.001) (data
not shown), which measures were not affected by drug treatments.
Control Gria12/2 mice spent more time in the open arms than
the control WT mice (F1,54 = 5.20, p,0.05) independent of the
treatments (Fig. 3A). No genotype or treatment effects were
observed on number of entries to open arms or on distance
travelled in the open arms (Fig. 3B–C).
Gria12/2 mice moved more than WT mice in the whole open
field arena during 3 min before the object was introduced (Fig. 4A;
F1,61 = 19.94, p,0.001), and chronic treatments with lithium and
valproate did not affect total movements (F2,61 = 1.10, p.0.05).
Gria12/2 mice visited the OF centre more frequently (Fig. 4C;
F1,61 = 4.85, p,0.05) than WT mice, but travelled similar
distances in the centre as them (Fig. 4B; F1,61 = 1.51, p.0.05).
Valproate increased the time spent in the central zone in WT
mice, but not in Gria12/2 mice (Fig. 4D; genotype6 treatment
interaction F2,61 = 3.78, p,0.05).
After the object was introduced in the OF for the next 3 min,
Gria12/2 mice kept moving more in the whole arena (Fig. 4E;
F1,61 = 92.90, p,0.001) as well as in the arena centre (Fig. 4F;
F1,61 = 55.23, p,0.001), independently of chronic treatments.
Gria12/2 mice visited the central zone with the object more often
(Fig. 4G; F1,61 = 81.15, p,0.001) and stayed there longer (Fig. 4H;
F1,61 = 22.32, p,0.001). Control Gria12/2 mice were in contact
with the object more frequently than WT mice, while treatments
of the Gria12/2 mice with valproate and lithium decreased the
frequency to the level of the corresponding WT mice (Fig. 4J;
F2,61 = 3.97, p,0.05).
Effects on Tests for Goal-directed Behaviours
Forced swimming test (FST) has been validated to examine
increased vigour and goal-directed behavioural pattern of mania
[39]. The increased goal-directed behaviour in both FST and tail
suspension test (TST) has been already reported in Gria12/2
mice [24]. In the FST, Gria12/2 mice were less immobile as
compared to the WT mice (Fig. 5; F1,60 = 23.87, p,0.001),
especially the control and valproate-treated groups. Lithium-
treated WT mice showed a trend towards being less immobile than
other WT groups (F2,60 = 3.13, p= 0.051). Kaplan-Meier analysis
showed that immobility was observed later in the control and
lithium-treated Gria12/2 mice than in the corresponding WT
mice (14.15, p,0.0001 and 5.73, p= 0.017, respectively, data not
shown).
In the TST, again the Gria12/2 mice were less immobile than
the WT mice (Fig. 5; F1,61 = 22.79, p,0.001), especially the
control and lithium-treated Gria12/2 mice. Valproate prolonged
the immobility in the Gria12/2 mice (F2,61 = 5.34, p,0.01).
Kaplan-Meier analysis showed that lithium-treated Gria12/2
mice demonstrated immobility later than control Gria12/2 mice
Drug Effects in an Animal Model for Hyperactive Disorders
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Figure 2. Effects of chronic lithium and valproate on hyperactivity of the Gria12/2 mice. Locomotor activities of WT and Gria12/2 mice
treated chronically with control diet and lithium- and valproate-supplemented diets in 5-min time intervals for the whole 2-h period (A, B) and
cumulative activities during the first and last 60 min of exposures to novel arena (C, D). Data are means 6 SEM (n= 14–27). ***p,0.001 for the
differences between genotypes after the same treatment; ##p,0.01, ###p,0.001 for the differences from controls of the same genotype (two-way
ANOVA followed by Bonferroni post-hoc test). In panel B, the earliest significant reduction from the control activity has been marked by #(p,0.05).
doi:10.1371/journal.pone.0100188.g002
Figure 3. Effects of chronic drug treatments on behaviour of Gria12/2mice in elevated-maze test of anxiety. Control Gria12/2 spent
more time in the open arms than control WT mice. Chronic lithium and valproate did not affect the time spent in (A) or entries to (B) or distances
travelled in open arms (C). Data are means 6 SEM (n= 7–12). **p,0.01 for the difference between genotypes after the same treatment (two-way
ANOVA followed by Bonferroni post-hoc test).
doi:10.1371/journal.pone.0100188.g003
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Figure 4. Effects of chronic drug treatments on open field activity and interaction with a novel object. Distance travelled in the whole
arena (A, E) and in the centre (B, F), entries to the centre (C, G) and time spent in the centre (D, H) during the first 3 min before the object was
introduced (A–D) and during the next 3 min when a novel object was located in the centre of arena (E–H). (I) Representative tracking paths for
Gria12/2 and WT mice during the 2nd 3-min period with an object, with a square in the centre delineating visual centre of arena. (J) Frequencies of
object interactions, scored using Ethograph software. Data are means 6 SEM (n= 6–15). *p,0.05, **p,0.01, ***p,0.001 for the differences between
genotypes after the same treatment; #p,0.05, ##p,0.01 for the differences from the control within the same genotype (two-way ANOVA followed
by Bonferroni post-hoc test).
doi:10.1371/journal.pone.0100188.g004
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(log-rank Mantel-Cox 14.32, p,0.0001) and lithium-treated WT
mice (13.50, p,0.0001) (data not shown).
We compared the immobility times in FST and TST tests that
were carried out in group- or individually-housed mice, respec-
tively. Within the Gria12/2 mice, no difference (t18 = 0.39, p.
0.05) was observed in the total immobility time of between FST
and TST [86.4615.1 s (12), mean 6 SEM, (n) and 96.1620.3 s
(9), respectively], and similarly, the immobility times of WT mice
in FST [176.568.8 s (12)] and TST [152.9612.2 s (14)] were
identical (t24 = 1.52, p.0.05). Also, lithium- (t20 = 0.46, p.0.05)
and valproate-treated (t11 = 1.03, p.0.05) Gria12/2 mice spent
similar times immobile in these tests, as did lithium- (t26 = 1.75, p.
0.05) and valproate-treated (t21 = 0.63, p.0.05) WT mice. It seems
that the housing conditions (individual or group-housing) hardly
affected the behavior of Gria12/2 and WT mice.
Effects on Social Interaction
Reciprocally initiated contacts were shorter-lasting but more
frequent in Gria12/2 mice than in WT mice (F2,60 = 4.64, p,
0.05), while valproate treatment levelled the Gria12/2 mice
behaviour to that of the WT mice (Fig. 6AB; treatment effect
F2,60 = 3.46, p,0.05 and F2,60 = 3.76, p,0.05 for the mean time
and frequency, respectively). Unlike WT, Gria12/2 mice spent
more time in passive interaction receiving contacts from other
mice (F1,60 = 4.24, p,0.05; data not shown), independently of the
treatments with lithium and valproate. They were engaged more
frequently in individual behaviour than WT mice (F1,60 = 31.22,
p,0.001) and lithium increased it over the control and valproate-
induced levels (F2,60 = 9.91, p,0.001; data not shown). Lithium
delayed the appearance of reciprocal contacts between the group
members in WT mice (log-rank Mantel-Cox 5.11, p,0.05), and
reciprocal contacts were observed later in control Gria12/2 than
WT mice (log-rank Mantel-Cox 4.70, p,0.05; data not shown).
Effects on Amphetamine-induced Hyperactivity
Gria12/2 and WT mice are similarly activated by acute
amphetamine challenge [26]. Here, we studied whether this
dopaminergic challenge would be affected by chronic drug
treatments. Gria12/2 mice preserved their higher locomotor
activity after 2 mg/kg amphetamine challenge throughout the 60-
min monitoring period as compared to WT mice, independently
of the chronic treatments with lithium and valproate
(F11,671 = 12.37, p,0.001 and F1,61 = 50.29, p,0.001 for time
intervals and genotype, respectively). Locomotor activity distances
(in meters as estimated by using Ethovision video-tracking) were
for the control, lithium and valproate groups of the WT mice:
311618 (mean 6 SEM, n = 14), 342622 (15) and 295611 (13),
respectively, and for the corresponding treatment groups of the
Gria12/2 mice: 507659 (9), 489632 (10) and 462624 (6),
respectively.
Effects on Sucrose Preference and Activity on Running
Wheels
To compare the mouse lines and to assess the effects of lithium
and valproate on hedonic behaviour, we tested the Gria12/2 and
WT mice for preference of sucrose-containing solution and for
running wheel activity. The Gria12/2 mice had higher prefer-
ence for sweet taste than WT mice (F1,57 = 8.87, p,0.01),
although all animals preferred sucrose solution over plain water.
Animals receiving lithium (Fig. 7A) and valproate (Fig. 7C)
increased sucrose consumption as compared with respective
control animals (F2,57 = 8.86, p,0.001). Interestingly, the control
WT mice reduced their consumption of sucrose during the first
(S4) and third (S6) session in the presence of running wheels
(F5,285 = 5.12, p,0.01). Otherwise the access to running wheels
little affected the preference for sucrose, although particularly the
valproate-treated WT mice clearly increased their activity on
running wheel on the last session (S6, Fig. 7D; F2,250 = 5.83, p,
0.01). Also lithium treatment increased running activity in the WT
mice on session S6 (Fig. 7B). Thus, no correlation (p.0.05) was
observed between running wheel activity and sucrose preference in
WT (0.01) or Gria12/2 mice (0.091).
Figure 5. Effects of chronic drug treatments in behavioural
despair paradigms. Gria12/2 mice were less immobile than the WT
mice in both the forced swimming (FST) and tail suspension (TST) tests.
Data are means 6 SEM (n= 7–13). **p,0.01, ***p,0.001 for the
differences between genotypes after the same treatment; #p,0.05 for
the differences from the control within the same genotype (two-way
ANOVA followed by Bonferroni post-hoc test).
doi:10.1371/journal.pone.0100188.g005
Figure 6. Effects of chronic drug treatments on social activity
on a new territory. Two or three animals on the same treatment were
observed for 10 min for reciprocal (simultaneously-initiated) contacts.
The contacts were shorter (A) but more frequent (B) among the control
Gria12/2 mice than among the WT mice. Chronic valproate, but not
lithium, moderated the activity of the Gria12/2mice to the level found
in the WT mice. Data are means 6 SEM (n= 6–15). *p,0.05, ***p,0.001
for the differences between genotypes after the same treatment; #p,
0.05 for the differences from the control within the same genotype
(two-way ANOVA followed by Bonferroni post-hoc test).
doi:10.1371/journal.pone.0100188.g006
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Effects of Anticonvulsants Topiramate and Lamotrigine
on Behavior of Gria12/2 Mice
In WT and Gria12/2 females, lamotrigine reduced cumulative
2-h novelty-induced LA in Gria12/2 mice (Fig. 8A–B; treatment
effect F1,35 = 5.93, p,0.05, genotype effect F1,35 = 46.38, p,
0.001), with the earliest significant reduction taking place at
20 min after starting the test (Fig. 8A).
There was no difference (t16 = 1.58, p.0.05) in LA of
topiramate-treated Gria12/2 mice between the two LA tests
[performed independently (351631 m (6), mean 6 SEM (n)) or
after other tests in the battery (457644 m (12)], nor within the
WT mice [t15 = 0.15, p.0.05; 271612 m (6) vs. 265630 m (11)].
Therefore, the data were pooled, analysed and presented in
Fig. 7C–D. The gender effect was not significant for either two 1-h
time intervals (F1,74.0.01, p.0.05, three-way ANOVA) and,
therefore, female and male data were pooled. Chronic treatment
with topiramate reduced 2-h novelty-induced hyperactivity
specifically in Gria12/2 mice in a time-dependent manner,
without affecting WT animals (Fig. 8C–D; F23,1794 = 3.09, p,0.01
for time interval 6 genotype 6 treatment interaction). The first
effect of topiramate on locomotor activity was observed after
20 min (Fig. 8C). In the EPM, treatment with topiramate reduced
the time that Gria12/2 mice stayed on the open arms (Fig. 8E;
F1,39 = 7.37, p,0.05 for genotype 6 treatment interaction),
suggesting anxiogenic or reduced risk-taking effects. Topiramate
increased total immobility time in Gria12/2 mice, but not in WT
mice (Fig. 8F, F1,43 = 5.16, p,0.05 for genotype 6 treatment
interaction) in the FST. Kaplan-Meier analysis showed that
topiramate-treated Gria12/2 mice demonstrated immobility
earlier than the control Gria12/2 mice (log-rank Mantel-Cox
4.26, p= 0.039).
Figure 7. Effects of chronic lithium and valproate on sucrose preference and running wheel activity Gria12/2 mice. Preference for
sucrose-containing solution over plain water, with and without an access to running wheels (RW) on sucrose-choice days (S1, S2 and S3) in animals
treated with lithium (A) and valproate (C). Running wheel activity during the sucrose-choice days (S1, S2, S3) in animals treated with lithium (B) and
valproate (D). Data are means 6 SEM (n= 6–14). *p,0.05, **p,0.01 for the differences between genotypes after the same treatment; #p,0.05,
###p,0.001 for the differences from the control treatment within the same genotype (two-way ANOVA followed by Bonferroni post-hoc test).
doi:10.1371/journal.pone.0100188.g007
Drug Effects in an Animal Model for Hyperactive Disorders
PLOS ONE | www.plosone.org 8 June 2014 | Volume 9 | Issue 6 | e100188
Discussion
In this study, we confirmed the elevated activity and highly
exploratory phenotype of Gria12/2 animals and conducted a
predictive assessment of efficacy of chronic treatments of standard
and novel, structurally and mechanistically different mood
stabilizers on a battery of behavioural tests for hyperactive aspects
of disorders, such as bipolar mania-like illness, schizophrenia and
schizoaffective disorder. We found that the treatments with
lithium, valproate, topiramate and lamotrigine all reduced
hyperactivity by increasing habituation of the Gria12/2 animals
in a novel environment and variably affected other behaviours.
Locomotor over-activity and increased exploration in open
space as well as over-reactivity to new objects were characteristic
for the Gria12/2 mice, indicative of high novelty seeking and
risk-taking behaviour. This behaviour was particularly sensitive to
both lithium and valproate. Dysfunctional exploration pattern has
been observed in bipolar manic and schizophrenic patients
[47,48]. Interestingly, bipolar manic patients are more mobile
and habituate faster than schizophrenic patients. Moreover,
bipolar patients are more interested in new objects and spend
more time near to the object [47,49]. Thus, specific behavioural
features differentiate bipolar patients from schizophrenic ones and
could be used as discriminating criteria between these disorders.
Moreover, behavioural disinhibition pattern was suggested as
endophenotype of bipolar disorder [50]. In the present work,
chronic treatment with the mood stabilizers studied here
attenuated the 2nd-h hyperlocomotion in a novel environment in
the Gria12/2 mice, but were not effective in reducing the initial
hyperactivity or the acutely exacerbated locomotion by amphet-
amine challenge. Gria12/2 mice show normal home-cage activity
pattern and diurnal rhythm [24] and amphetamine elevates the
activity similarly as is the WT mice [26], which suggest that their
abnormal novelty-induced hyperactivity resembles more mania-
type behaviour than attention deficit hyperactivity disorder-type of
behaviour.
Novelty-induced hyperactivity of the Gria12/2 mice is greatly
reduced by acute blockade of AMPA receptors with NBQX [24]
and by mGlu2/3 receptor agonist LY354740 [51], which results
are consistent with hyperactive glutamate system in the Gria12/2
mice. Our recent c-Fos mapping data suggest overactivity of the
dorsal hippocampus of the Gria12/2 animals in a novel situation
Figure 8. Effects of chronic treatments with anticonvulsants lamotrigine and topiramate on behavior of Gria12/2 mice. Cumulative
locomotor activities of Gria12/2 and WT mice treated chronically with lamotrigine- or topiramate-supplemented chow for 5-min time intervals (A, C)
and for the whole 2-h experiment (B, D). Data are means6 SEM (n= 8–27). In A and C, the earliest significant point from the control activity has been
marked by #(p,0.05). Topiramate treatment reduced the time spent in open arms of elevated-plus maze (E; means 6 SEM, n= 9–12) and increased
immobility time in forced swimming test (F; means 6 SEM, n = 11–12) in Gria12/2 mice. **p,0.01, ***p,0.001 for the difference between
genotypes after the same treatment; #p,0.05, ###p,0.001 for the difference from the control within the same genotype (two-way ANOVA followed
by Bonferroni post-hoc test).
doi:10.1371/journal.pone.0100188.g008
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[24,51]. Of the mood stabilizers studied here, topiramate and
lamotrigine reduce glutamate functions by inhibiting glutamate
receptors and glutamate release, respectively [52–54], which could
explain their efficacy. Also treatment with lithium is known to
indirectly affect NMDA-type glutamate receptor function, subunit
expression and phosphorylation and activation of the related
intracellular signalling cascades, such as phospholipase PLA2 and
nitric oxide (NO) pathways [55–58], while the NMDA receptor
antagonists potentiate the actions of lithium [59]. However, other
mechanisms than glutamate antagonism are likely to be involved
also, since valproate is not known to antagonize the glutamate
system, and indeed valproate has failed to protect from NMDA-
induced seizures [60]. Protein kinase C and extracellular signal-
regulated kinase cascades constitute as shared targets for lithium
and valproate and are involved in mediating their anti-manic
actions on various facets of the disease [61]. These pathways may
also be among the mediators of the anti-hyperactive effect of
lithium and valproate in the Gria12/2 model of abnormal
hyperactivity.
Chronic treatment with lithium could also suppress hyperloco-
motion via presynaptic mechanisms that decrease release of
catecholamines or inhibit their synthesis [62]. Indeed, dopamine
D2 receptor antagonist haloperidol somewhat reduces hyperac-
tivity in the Gria12/2 and WT mice [25]. However, depletion of
dopamine levels by inhibition of tyrosine hydroxylase did not
affect the locomotor phenotype of these mice [22], neither was
there any differential activation of the ventral tegmental area
dopaminergic (VTA DA) neurons or striatal neurons between
Gria12/2 and WT mice after 2 h in novel environment [24], and
therefore, dopaminergic mechanisms are unlikely to decisively
contribute to the hyperlocomotor phenotype. On the other hand,
glutamate receptor neuroplasticity in VTA DA neurons is
associated with the effects of rewarding drugs of abuse [63,64],
and this neuroplasticity process might be deficient in Gria12/2
mice as the opioid morphine failed to induce an increase of
AMPA/NMDA ratio of VTA DA neurons in Gria12/2 mice like
it did in WT animals [65]. State-dependent place conditioning
with morphine is abnormal in Gria12/2 mice [65]. In the present
study, of the two naturally rewarding stimuli, sucrose drinking and
running wheel activity, only sucrose drinking test was useful to
discriminate between the Gria12/2 and WT mice, while running
activity did not differ between the genotypes. Dopaminergic
projection from the VTA is important for appetitive behaviour
and hedonic responses to palatable food [66], with a lesion of this
projection decreasing sucrose intake [67]. Activation of VTA DA
neurons by disinhibition via cannabinoid CB1 receptor-dependent
mechanism has been linked to rewarding properties of voluntary
running wheel activity [68]. However, we found no interaction
between accesses to sucrose drinking and running wheels in
Gria12/2 and WT mice on control diet, and unexpectedly,
treatment with lithium and valproate rather increased than
suppressed sucrose preference. Unlike sucrose consumption, which
increased in both Gria12/2 and WT mice by valproate and
lithium, running activity increased significantly only in WT
animals. Rewarding responses were not consistently affected by
the drugs in the present study.
The main effects of the drugs studied here were on hyperactivity
of the Gria12/2 animals, but they produced also some effects on
other behaviours. Chronic lithium reduced the frequency of
contacts to new objects in the open field, as did valproate.
Valproate induced an anxiolytic-like effect in the WT mice that
was not observed in the Gria12/2 mice. In social interaction test,
valproate prolonged reciprocal social contacts only in the Gria12/
2 mice. The effects of lithium and valproate in different tests
might be related to increased habituation. Topiramate had an
anxiogenic-like effect in the Gria12/2 animals. Topiramate and
lamotrigine were not studied here as widely as lithium and
valproate for other behaviours than hyperactivity. Even though we
did not find any significant difference in the behavior of mice
differently housed (see the immobility times in FST vs. TST in the
Results section), deprivation of social contacts is known to impair
behavior [69]. Isolation of rats increases motivational value of
sucrose [35] and number of social contacts [70,71]. Multiple
testing can also have a substantial influence on behavior [72]. In
the present study, locomotor activity of mice with previous testing
history was similar compared to those naı¨ve to experimentation.
However, this does not straightforwardly imply that the behavior
observed in other tests in a multiple testing battery would not be
affected by the prior testing and associated stress. Still, behavioural
test batteries in rodents are widely used and favoured for wide
behavioural screening and designed to cover many distinct
behavioural domains relevant for human neuropsychiatric disor-
ders [73]. We conclude that in the present experiments, the main
effects that regulated the behaviour, especially the hyperactivity,
were the mouse genotype and chronic drug treatments.
Rodent models in neuropsychiatry usually phenocopy only
some aspects of a disease, such as hyperactivity. Hyperactivity is a
shared feature among several psychiatric conditions, such as
mania, anxiety, attention deficit hyperactivity disorder and autism
spectrum disorders, in addition to some forms of schizophrenia.
Animal models are valuable tools for studying predictive validity of
treatments, but even with partial face validity, they usually have
weak construct validity [74]. In Gria12/2 mouse line, hyperac-
tivity is pronounced and concomitant with other behavioral
abnormalities indicative of highly disinhibited behavior. More-
over, as we show here, their behavioral abnormalities and deficits
are controlled by mood stabilizing medications. Importantly,
AMPA receptors, as determinants of synaptic plasticity might have
a critical role during late adolescence for the onset of cognitive and
behavioral abnormalities for neuropsychiatric disorders. Ablation
of GluA1 subunit from the hippocampus in late adolescence
reproduced all behavioural abnormalities of mice with global
deletion of GluA1 subunit, except for social deficits [75]. However,
aggressiveness as a correlate of irritability and easily provoked
behavior is lacking in Gria12/2 mice [29]. There are two other
interesting glutamate-linked models for mania-like hyperactivity.
They include the mice deficient in kainate receptor GluK2 subunit
(Grik22/2) [76], in which chronic treatment with lithium reduces
hyperactivity, risk-taking behaviour and aggressive manic displays,
and the Shank3 overexpressing mice [77], in which acute valproate,
but not chronic lithium, reduces hyperactivity. While SHANK
proteins are postsynaptic density scaffolding proteins in glutamate
synapses and implicated in a number of neuropsychiatric disorders
[78], heteromeric kainate receptors, assembling also GluK2
subunits, regulate presynaptically and postsynaptically neurotrans-
mission of both interneurons and principal neurons [79,80].
Together with the present results on Gria12/2 mouse line, these
models suggest an important role for excitatory glutamate
transmission in disorders with hyperactivity.
In conclusion, this is the first report to describe behavioural
effects of chronic treatments with different clinically used mood
stabilizers in the AMPA receptor GluA1 subunit-deficient mice
using test batteries specific to some hyperactive facets of bipolar
illness, schizophrenia and schizoaffective disorder. Gria12/2 mice
showed disinhibited risk-taking behaviour, hyperlocomotion and
social deficits, which were at least partially reversed by mood
stabilizers, and therefore, we suggest that this mouse line can be
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used as a model for screening for novel drugs to treat hyperactive
neuropsychiatric disorders.
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